JPRN-UMIN000052237招募中Unknown
Evaluation the clinical utility of KRAS mutation assay using tumor samples (tissue, cytology) and blood samples in patients with pancreatic cancer. - Evaluation the clinical utility of KRAS mutation assay using tumor samples (tissue, cytology) and blood samples in patients with pancreatic cancer.
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients whose participation in this study is decided inappropriate by the principal investigator or subinvestigator. 2. Patients who are strongly suspected to have a specific type of pancreatic cancer based on tumor markers (e.g., IPMC (intraductal papillary mucinous carcinoma), NEN (neuroendocrine neoplasm)).
研究者
相似试验
已完成
不适用
A clinical study of relevance to KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerColorectal cancerJPRN-UMIN000013154Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences20
招募中
不适用
Clinical relevance of KRAS and GNAS Mutationen in cell-free DNA and circulating epithelial cells regarding the development of pancreatic cancer in IPMN patientsD13.6PancreasDRKS00023356niversitätsklinikum Hamburg-Eppendorf100
进行中（未招募）
1 期
A study to investigate changes in the amount of mutations in patients with Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10033602 Term: Pancreatic adenocarcinoma resectable System Organ Class: 100000004864EUCTR2018-002094-22-ESFundación de investigación de HM Hospitales20
尚未招募
不适用
Prevalence of two mutations (KRAS and BRAF) in patients diagnosed with Colorectal Cancer.CTRI/2013/09/004023Dr Prachi S Patil200
招募中
不适用
Comparative analysis of KRAS and EGFR mutation detection in liquid biopsy vs tissue biopsy in patients with NSCLCNon-small-cell lung carcinoma10038666lung cancerNL-OMON48625Jeroen Bosch Ziekenhuis150